CNTX - NASDAQ
Context Therapeutics Inc.
$2.17
-10%Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
At a Glance
Live SnapshotContext Therapeutics Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Context Therapeutics Inc. Balance Sheet
CNTX • NASDAQ
| Context Therapeutics Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
66M | 94.4M | 14.4M | 35.5M | 49.6M | 341K | 226.6K | |
66M | 94.4M | 14.4M | 35.5M | 49.6M | 341K | 226.6K | |
0.0 | 0.0 | 0.0 | 0.0 | 1.6M | 8.7K | 13K | |
2.4M | 3.5M | 1.6M | 2.4M | 0.0 | 0.0 | 0.0 | |
68.4M | 97.9M | 16M | 37.9M | 51.3M | 349.7K | 239.6K | |
NON-CURRENT ASSETS | |||||||
140.1K | 230.8K | 15.5K | 79.5K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 50.4K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 32.8K | 0.0 | 117.6K | 33.9K | |
140.1K | 230.8K | 15.5K | 112.3K | 50.4K | 117.6K | 33.9K | |
68.5M | 98.1M | 16.1M | 38M | 51.3M | 467.3K | 273.5K | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
2.5M | 1.5M | 2.4M | 936.3K | 1.8M | 2.7M | 2.1M | |
2.5M | 1.5M | 2.4M | 936.3K | 1.8M | 2.7M | 2.1M | |
0.0 | 247.2K | 1.1M | 1.4M | 1.1M | 956K | 197.5K | |
112.1K | 0.0 | 0.0 | 0.0 | 0.0 | 5.9M | 21.8M | |
0.0 | 107.3K | 0.0 | 55.1K | 0.0 | 0.0 | 0.0 | |
5.4M | 941.7K | 661.3K | 853.5K | 85.5K | 0.0 | 0.0 | |
8M | 2.7M | 4.2M | 3.2M | 3M | 9.5M | 24.1M | |
NON-CURRENT LIABILITIES | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 69K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.8M | 126K | |
0.0 | 112.1K | 0.0 | 0.0 | 0.0 | 7.8M | 126K | |
0.0 | 219.4K | 0.0 | 55.1K | 0.0 | 0.0 | 0.0 | |
8M | 2.9M | 4.2M | 3.2M | 3M | 17.4M | 24.2M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 126K | |
91.9K | 89.7K | 16K | 16K | 16K | 332.0 | 324.0 | |
191.3M | 190M | 79.9M | 78.8M | 77.5M | 1.9M | 1.5M | |
-130.9M | -94.8M | -68.1M | -44.1M | -29.3M | -18.8M | -25.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -126K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 126.1K | |
60.5M | 95.3M | 11.9M | 34.8M | 48.3M | -16.9M | -24M | |
60.5M | 95.3M | 11.9M | 34.8M | 48.3M | -16.9M | -24M | |
SUMMARY | |||||||
68.5M | 98.1M | 16.1M | 38M | 51.3M | 467.3K | 273.5K | |
0.0 | 0.0 | 0.0 | 0.0 | 50.4K | 0.0 | 0.0 | |
112.1K | 219.4K | 0.0 | 55.1K | 0.0 | 6M | 21.8M | |
-65.9M | -94.2M | -14.4M | -35.4M | -49.6M | 5.6M | 21.6M | |
89,704,194 | 89,704,194 | 89,704,194 | 89,704,194 | 89,704,194 | 89,704,194 | 89,704,194 |
SEC Filings
CNTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | April 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 13, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 |
Related Guides
Continue your CNTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.